The study objective was to evaluate the efficacy and safety of transscleral cyclophotocoagulation (TSCPC) using micropulse diode laser treatment in patients with various types of glaucoma.
Evaluation of the efficacy and safety of a new form of transscleral cyclophotocoagulation (TSCPC) using micropulse diode laser treatment in patients with various types of glaucoma. In this study, 810 nm infrared diode laser radiation in the micro- pulse mode was used in conjunction with a G probe (IRIDEX Medical Instruments, Mountain View, CA, USA). The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser set on micro- pulse mode, delivered over 100-200 seconds (envelope of micropulses) depending on severity of the case and other patient factors. With duty cycle 31.3% (This translates to 0.5 ms "on" time and 1.1 ms "off" time), which allows the tissue to cool down between laser shots, thus greatly reducing thermal damage.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors. Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively.
Benha University
Banhā, Other, Egypt
Intraocular pressure (IOP)
significant change in IOP in mmHg.
Time frame: Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively
best corrected visual acuity (BCVA)
change in BCVA using snellen's chart
Time frame: Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively
complication rate.
Describing any complications related to the procedure.
Time frame: Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively
change in number of postoperative glaucoma medications.
Number of postoperative glaucoma medications.
Time frame: Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively
retreatment rate.
percentage of patients needing further treatment.
Time frame: Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.